BiondVax in the News
In case you missed it, we thought we'd share some recent press about BiondVax and our universal flu vaccine candidate M-001:
A New Push for a Universal Flu Vaccine
“The M-001 vaccine approach is exciting”, says Kathleen Sullivan, chief of the Division of Allergy and Immunology at The Children’s Hospital of Philadelphia, who was not involved in the work. “The conceptualization of this vaccine is really innovative.”
A Checkup for the Flu Vaccine
BiondVax’s M-001 vaccine similarly elicits T cell responses to conserved viral epitopes from influenza A and B strains and is in trials as a standalone vaccine and as a priming step before administration of the seasonal flu vaccine...
NIAID-Sponsored Trial of a Universal Influenza Vaccine Begins
“The 2017-2018 influenza season in the United States was among the worst of the last decade and serves as a reminder of the urgent need for a more effective and broadly protective influenza vaccine,” said NIAID Director Anthony S. Fauci, M.D. “An effective universal influenza vaccine would lessen the public health burden of influenza, alleviate suffering and save lives.”
Also: